基于复合系统协同度模型的上海市医药制造业创新系统协同度研究

发布时间：2018-03-28 07:47

本文选题：复合系统协同度模型　切入点：上海　出处：《中国药房》2017年19期

【摘要】：目的:研究上海医药制造业产业创新系统的协同情况,为进一步提升上海医药企业的行业竞争力提供参考。方法:基于复合系统协同度模型,选取2006-2014年上海医药制造业创新系统的创新环境(S_1)、创新技术研发(S_2)、创新技术吸收(S_3)以及创新产出(S_4)四个子系统方面的序变量(G)设定协同度模型,依次计算各序变量的序参量、有序度及协同度。结果与结论:S_1~S_4分别得到4、4、4、2个序参量;2006-2014年上海市医药制造业的协同度在-0.195~0.202之间,平均值为-0.068,整体处于"逆协同"和"不协同"水平。可见,上海医药制造业创新系统内部发展状态较为无序,建议医药制造业从创新环境的稳定性和促进技术吸收这两个核心影响因素入手进行改革,包括加速医药产业转型升级,创造稳定创新环境;加大医药产业创新投入,提升技术吸收与自主创新水平;加强域内外合作交流等,切实提升上海医药制造业创新系统协同度水平。
[Abstract]:Objective: to study the synergy of Shanghai pharmaceutical manufacturing industry innovation system, and to provide a reference for further enhancing the industry competitiveness of Shanghai pharmaceutical enterprises. Selecting the innovation environment of Shanghai pharmaceutical manufacturing innovation system from 2006 to 2014, the following four subsystems: innovation technology research and development, innovation technology absorption, innovation technology absorption, and innovation output S4) are selected to set up a synergy degree model, and the order parameters of each order variable are calculated in turn. Results and conclusion the coordination degree of Shanghai pharmaceutical manufacturing industry from 2006 to 2014 was -0.195 / 0.202, with an average value of -0.068, and the whole was at the level of "inverse synergy" and "non-synergy". The results and conclusions showed that: (1) the degree of coordination in the pharmaceutical manufacturing industry of Shanghai from 2006 to 2014 was -0.195 / 0.202, with an average of -0.068, and the whole was at the level of "inverse synergy" and "non-synergy". The internal development of Shanghai Pharmaceutical Manufacturing Innovation system is relatively disordered. It is suggested that the pharmaceutical manufacturing industry should start with the two core influencing factors, namely, the stability of the innovation environment and the promotion of technology absorption, including accelerating the transformation and upgrading of the pharmaceutical industry. Create a stable innovation environment, increase innovation investment in the pharmaceutical industry, enhance the level of technology absorption and independent innovation, strengthen cooperation and exchanges within and outside the region, and effectively enhance the level of synergy in the innovation system of Shanghai pharmaceutical manufacturing industry.
【作者单位】：南京中医药大学卫生经济管理学院;
【分类号】：F224;F273.1;F426.72

【相似文献】